Saturday, July 11, 2026

Drug profile · INN

radium ra223 dichloride

radium ra223 dichloride (XOFIGO) is a radiotherapy agent.

EMA: approved Various (V10) V10XX03
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — radium ra223 dichloride
Class
Various (V10)
Route
Patents
0
Programs
6
Data quality
0.83

Quick answer

radium ra223 dichloride (XOFIGO) is a radiotherapy agent.

Key facts

INN radium ra223 dichloride
Brand XOFIGO
Mechanism Radiotherapy agent
Therapeutic class Various (V10)
ATC code V10XX03

Mechanism of action

Radiotherapy agent

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Xofigo 1100 kBq/mL solution for injection Phase 3 · Ningbo Cancer Hospital · metastatic Castration-Resistant Prostate Cancer (mCRPC)
  2. Xtandi - soft capsules for Castration resistant prostate c… Phase 3 · Ningbo Cancer Hospital · Castration resistant prostate cancer patients metastatic to
  3. IRST185.04 Phase 2 · Istituto Gentili Italia · metastatic castration resistant prostate cancer (mCRPC), sym
  4. Radium-223 dichloride (Xofigo, BAY88-8223) Phase 2 · Bayer HealthCare Animal · Breast Neoplasms
  5. SAKK 08/23 Phase 2 · Ningbo Cancer Hospital · Metastatic castration-resistant prostate cancer
  6. 20510 Approved · Bayer · metastatic castrate resistant prostate cancer (mCRPC)

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Frequently asked questions

What is radium ra223 dichloride?

radium ra223 dichloride (XOFIGO) is a radiotherapy agent.

What is the brand name for radium ra223 dichloride?

XOFIGO is a marketed brand name for radium ra223 dichloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.